If exciting small cap ASX shares like Whispir Ltd (ASX: WSP) are too small for your tastes, then you might want to have a look at the mid cap side of the market.
At this side of the market I believe there are a number of shares which have the potential to grow very strongly in the future. Perhaps even to the point that they one day become large caps.
Three top mid cap ASX shares to consider buying are listed below:
BINGO Industries Ltd (ASX: BIN)
BINGO is a leading waste management company which I think has a lot of potential. This is thanks to its expansion opportunities in Australia and the game-changing acquisition of rival Dial a Dump Industries. The addition of Dial a Dump Industries has transformed BINGO into a fully vertically integrated business from collections to landfill. Although the pandemic is likely to weigh on its short term performance, I think it is worth focusing on its very positive long term prospects.
EML Payments Ltd (ASX: EML)
Another mid cap share to consider buying is EML Payments. It is a payments company with a focus on digital gift cards and pre-paid cards. It also provides the technology that supports certain buy now pay later offerings. The company has been growing at a very strong rate over the last few years. Pleasingly, I believe it is well-positioned to continue this positive trend once the pandemic passes. Especially following the recent acquisition of Prepaid Financial Services. This acquisition gives EML exposure to banking as a service (BaaS) and could be a key driver of growth in the coming years.
Opthea Ltd (ASX: OPT)
A final mid cap share to look at is Opthea. It is a developer of novel biologic therapies for the treatment of eye diseases. Last year Opthea reported very positive Phase 2b study results for its OPT-302 combination therapy. If its phase 3 trial is successful, the company has a multi-billion dollar opportunity treating wet age-related macular degeneration and diabetic macular edema. Another positive is that Opthea has a very strong balance sheet and appears well-funded to see OPT-302 through its remaining trials.
